Wang ES, Montesinos P, Minden MD, Sibai H, Lee J-H, Heuser M, Naoe T, Chou W-C, Laribi K, Esteve J, Altman JK, Havelange V, Watson A-M, Fumagalli M, Patkowska E, Hill JE, Gill SC, Pandya BJ, Chen C, Hasabou N. Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study. haematol [Internet]. 2020Sep.10 [cited 2026Sep.15];. Available from: https://haematologica.org/article/view/14388